Potential of Volatile Organic Compound (VOC) and Serum Interleukin-17 for Evaluation of Lung Cancer Therapy Based on Response Evaluation Criteria in Solid Tumors (RECIST)
Abstract
Background: Lung cancer is the second leading cause of death in the world due to delays in diagnosis. Non-invasive Volatile Organic Compound (VOC) method to diagnose and monitor the progressivity of lung cancer. Interleukin-17 (IL-17) has an important role in the progression and treatment of lung cancer. Objective evaluation of chemotherapy using Response Evaluation Criteria in Solid Tumors (RECIST 1.1). This study aims to determine the relationship between VOC, IL-17, and lung cancer chemotherapy response based on RECIST at Saiful Anwar General Hospital, East Java.
Methods: In a prospective cohort study, 47 lung cancer patients received first-line chemotherapy pre and post-three series of chemotherapy. Exhaled breath was collected with Tedlar Bags and then analyzed with µβreath for VOC. IL-17 in blood serum is determined by an enzyme-linked immunosorbent assay (ELISA). The data were analyzed using the Wilcoxon, Mann-Whitney, and Spearman tests.
Results: There were significant in VOC Components (p < 0.05) Formaldehyde (CH2O), Toluene (C7H8), Acetone (C3H6O), Hexane (C6H14), Methane (CH4), RECIST non-target lesions, and new lesions pre and post-three series of chemotherapy but not found in IL-17. Acetone (C3H6O) pre and Methane (CH4), IL-17 post-three series of chemotherapy based on RECIST Overall Response (OR) found significant. The analysis showed a positive correlation between Formaldehyde (CH2O) pre and Methane (CH4), IL-17 post-three series of chemotherapy based on RECIST OR, but a negative correlation between Acetone (C3H6O) pre-chemotherapy.
Conclusions: There was a significant decrease in formaldehyde, toluene, hexane, methane and an increase in acetone in lung cancer patients pre and post-three series of chemotherapy. There was a significant relationship between formaldehyde, acetone pre-chemotherapy, and methane, IL-17 post-three series of chemotherapy based on the RECIST overall response
Keywords
DOI: 10.33371/ijoc.v18i4.1127
Article Metrics
Abstract View: 404, 
PDF Download: 275
References
Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Contemp Oncol (Pozn). 2021;25:45–52.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.
Jia Z, Zhang H, Ong CN, Patra A, Lu Y, Lim CT, et al. Detection of Lung Cancer: Concomitant Volatile Organic Compounds and Metabolomic Profiling of Six Cancer Cell Lines of Different Histological Origins. ACS Omega. 2018;3:5131–40.
Chen D-T, Chan W, Thompson ZJ, Thapa R, Beg AA, Saltos AN, et al. Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer. PLoS One. 2021;16:e0252041.
Seijo LM, Peled N, Ajona D, Boeri M, Field JK, Sozzi G, et al. Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges. J Thorac Oncol. 2019;14:343–57.
Buma AIG, Muller M, de Vries R, Sterk PJ, van der Noort V, Wolf-Lansdorf M, et al. eNose analysis for early immunotherapy response monitoring in non-small cell lung cancer. Lung Cancer. 2021;160:36–43.
van Geffen WH, Lamote K, Costantini A, Hendriks LEL, Rahman NM, Blum TG, et al. The electronic nose: emerging biomarkers in lung cancer diagnostics. Breathe (Sheff). 2019;15:e135–41.
Song L, Ma S, Chen L, Miao L, Tao M, Liu H. Long‐term prognostic significance of interleukin‐17‐producing T cells in patients with non‐small cell lung cancer. Cancer Science. 2019;110:2100.
Beer L, Hochmair M, Haug AR, Schwabel B, Kifjak D, Wadsak W, et al. Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung Cancer. Clin Nucl Med. 2019;44:535–43.
Dubin S, Griffin D. Lung Cancer in Non-Smokers. Mo Med. 2020;117:375–9.
Rodak O, Peris-Díaz MD, Olbromski M, Podhorska-Okołów M, Dzięgiel P. Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy. Cancers (Basel). 2021;13:4705.
Huang J, Deng Y, Tin MS, Lok V, Ngai CH, Zhang L, et al. Distribution, Risk Factors, and Temporal Trends for Lung Cancer Incidence and Mortality: A Global Analysis. Chest. 2022;161:1101–11.
Deshpand R, Chandra M, Rauthan A. Evolving trends in lung cancer: Epidemiology, diagnosis, and management. Indian Journal of Cancer. 2022;59:S90.
Nath A, Sathishkumar K, Das P, Sudarshan KL, Mathur P. A clinicoepidemiological profile of lung cancers in India - Results from the National Cancer Registry Programme. Indian J Med Res. 2022;155:264–72.
Wang B-Y, Huang J-Y, Chen H-C, Lin C-H, Lin S-H, Hung W-H, et al. The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients. J Cancer Res Clin Oncol. 2020;146:43–52.
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20:497–530.
Boonsong T, Usaha S, Nakwan N, Ruklerd T, Khongthong P, Chang A. Survival Analysis and Clinical Outcomes between Paclitaxel and Carboplatin Versus Carboplatin and Gemcitabine in Patients with Advanced-stage Non-small-cell Lung Cancer: A Single-center Cohort Study. Asian Pac J Cancer Prev. 2022;23:3371–8.
Rastogi A, Baheti A, Patra A, Tirumani S. Tumor Response Criteria in Oncoimaging: RECIST Criteria and beyond—Part 1. Journal of Gastrointestinal and Abdominal Radiology. 2019;02.
Hanna GB, Boshier PR, Markar SR, Romano A. Accuracy and Methodologic Challenges of Volatile Organic Compound–Based Exhaled Breath Tests for Cancer Diagnosis. JAMA Oncol. 2019;5:e182815.
Peled N, Fuchs V, Kestenbaum EH, Oscar E, Bitran R. An Update on the Use of Exhaled Breath Analysis for the Early Detection of Lung Cancer. Lung Cancer (Auckl). 2021;12:81–92.
Güntner A, Koren V, Chikkadi K, Righettoni M, Pratsinis S. E-Nose Sensing of Low-ppb Formaldehyde in Gas Mixtures at High Relative Humidity for Breath Screening of Lung Cancer? ACS Sensors. 2016;1.
Listiandoko RD, Setyawan UA, Astuti T. EP01. 01-004 The Correlation Between Exhaled Volatile Organic Compounds Using Breath Analyzer and Interleukin-23 (IL-23) in Lung Cancer. Journal of Thoracic Oncology. 2022 Sep 1;17(9):S161.
Dananjaya A, Setyawan UA, Djajalaksana S, Wardoyo AYP. Change in Exhaled Volatile Organic Compounds (VOC) Profile and Interleukin-17 Serum in Lung Cancer Patient. Jurnal Respirologi Indonesia. 2023;43:9–14.
Chang JE, Lee DS, Ban SW, Oh J, Jung MY, Kim SH, et al. Analysis of volatile organic compounds in exhaled breath for lung cancer diagnosis using a sensor system. Sensors and Actuators B: Chemical. 2018;255:800–7.
Jia Z, Patra A, Kutty VK, Venkatesan T. Critical Review of Volatile Organic Compound Analysis in Breath and In Vitro Cell Culture for Detection of Lung Cancer. Metabolites. 2019;9:52.
Jian RS, Chu JA, Song LY, Lo EW, Lu CJ. Simultaneous Monitoring of ppmv Level Methane and ppbv Level VOCs Near Industrial Sources Using a Real-Time GC [Internet]. In Review; 2023 Feb. Available from: https://www.researchsquare.com/article/rs-2520838/v1
Pan Q, Liu QY, Zheng J, Li YH, Xiang S, Sun XJ, et al. Volatile and semi-volatile organic compounds in landfill gas: Composition characteristics and health risks. Environment International. 2023;174:107886.
Gashimova EM, Temerdashev AZ, Porkhanov VA, Polyakov IS, Perunov DV. Volatile Organic Compounds in Exhaled Breath as Biomarkers of Lung Cancer: Advances and Potential Problems. J Anal Chem. 2022;77:785–810.
Wang XF, Zhu YT, Wang JJ, Zeng DX, Mu CY, Chen YB, et al. The prognostic value of interleukin-17 in lung cancer: A systematic review with meta-analysis based on Chinese patients. PLoS One. 2017;12:e0185168.
Chen G, Zhang P-G, Li JS, Duan JJ, Su W, Guo SP, et al. Th17 cell frequency and IL-17A production in peripheral blood of patients with non-small-cell lung cancer. J Int Med Res. 2020;48:300060520925948.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Email this article 
